Wells Fargo analyst Sam Reid initiated coverage on several homebuilding and building products stocks.
The analyst said recent volatility in the homebuilding space offers an opportunity. Reid cites that the high rates pose a barrier for resales but offer interesting TAM implications amid low existing home sales (EHS) builders.
Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches towards the U.S. market.
Goldman Sachs analyst Benjamin Miller took a look at online travel stocks, now that the industry has gone past COVID-19 and increasingly moving beyond the pent-up demand post-pandemic.